Charles Rhyee
Stock Analyst at TD Cowen
(2.09)
# 2,954
Out of 5,157 analysts
78
Total ratings
43.4%
Success rate
-5.8%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Upgrades: Buy | $15 | $9.29 | +61.46% | 5 | Mar 9, 2026 | |
| IQV IQVIA Holdings | Upgrades: Buy | $174 → $213 | $171.55 | +24.16% | 4 | Mar 9, 2026 | |
| VEEV Veeva Systems | Maintains: Buy | $380 → $300 | $186.84 | +60.57% | 5 | Mar 5, 2026 | |
| TDOC Teladoc Health | Maintains: Hold | $8 → $6 | $5.43 | +10.50% | 7 | Feb 26, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $251 → $235 | $168.56 | +39.42% | 7 | Feb 20, 2026 | |
| TALK Talkspace | Maintains: Buy | $6 → $9 | $5.17 | +74.25% | 3 | Feb 20, 2026 | |
| ICLR ICON Public Limited Company | Upgrades: Buy | $183 → $120 | $105.53 | +13.72% | 7 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Upgrades: Hold | $462 → $419 | $474.37 | -11.67% | 7 | Feb 18, 2026 | |
| CI The Cigna Group | Maintains: Buy | $333 → $338 | $260.79 | +29.61% | 2 | Feb 9, 2026 | |
| MCK McKesson | Maintains: Buy | $1,000 → $1,012 | $940.00 | +7.66% | 5 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $42.49 | +8.26% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.22 | +170.88% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $400 | $352.30 | +13.54% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $100 | $76.03 | +31.53% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $183 → $225 | $215.58 | +4.37% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $29.74 | -9.21% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $5.51 | +807.64% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $5.86 | +855.63% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $8.90 | +3,046.07% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $2.98 | +1,577.85% | 2 | Jun 21, 2022 |
Fortrea Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $15
Current: $9.29
Upside: +61.46%
IQVIA Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $174 → $213
Current: $171.55
Upside: +24.16%
Veeva Systems
Mar 5, 2026
Maintains: Buy
Price Target: $380 → $300
Current: $186.84
Upside: +60.57%
Teladoc Health
Feb 26, 2026
Maintains: Hold
Price Target: $8 → $6
Current: $5.43
Upside: +10.50%
Charles River Laboratories International
Feb 20, 2026
Maintains: Buy
Price Target: $251 → $235
Current: $168.56
Upside: +39.42%
Talkspace
Feb 20, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $5.17
Upside: +74.25%
ICON Public Limited Company
Feb 18, 2026
Upgrades: Buy
Price Target: $183 → $120
Current: $105.53
Upside: +13.72%
Medpace Holdings
Feb 18, 2026
Upgrades: Hold
Price Target: $462 → $419
Current: $474.37
Upside: -11.67%
The Cigna Group
Feb 9, 2026
Maintains: Buy
Price Target: $333 → $338
Current: $260.79
Upside: +29.61%
McKesson
Feb 5, 2026
Maintains: Buy
Price Target: $1,000 → $1,012
Current: $940.00
Upside: +7.66%
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $42.49
Upside: +8.26%
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.22
Upside: +170.88%
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $352.30
Upside: +13.54%
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $76.03
Upside: +31.53%
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $215.58
Upside: +4.37%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $29.74
Upside: -9.21%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $5.51
Upside: +807.64%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $5.86
Upside: +855.63%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $8.90
Upside: +3,046.07%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $2.98
Upside: +1,577.85%